Literature DB >> 17001803

Dasatinib.

Hagop Kantarjian, Elias Jabbour, Joanne Grimley, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17001803     DOI： 10.1038/nrd2135

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  47 in total

Review 1.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

Review 2.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

3.  Monitoring Cell-surface N-Glycoproteome Dynamics by Quantitative Proteomics Reveals Mechanistic Insights into Macrophage Differentiation.

Authors:  Mathias Kalxdorf; Stephan Gade; H Christian Eberl; Marcus Bantscheff
Journal:  Mol Cell Proteomics       Date:  2017-03-23       Impact factor: 5.911

4.  Improved angiostatic activity of dasatinib by modulation with hydrophobic chains.

Authors:  Emilia Păunescu; Catherine M Clavel; Patrycja Nowak-Sliwinska; Arjan W Griffioen; Paul J Dyson
Journal:  ACS Med Chem Lett       Date:  2015-01-30       Impact factor: 4.345

5.  Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A.

Authors:  Jamie L Dargart; Kamonwan Fish; Leo I Gordon; Richard Longnecker; Osman Cen
Journal:  Antiviral Res       Date:  2012-05-16       Impact factor: 5.970

6.  Dasatinib Suppresses TGFβ-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis.

Authors:  Ryota Kanemaru; Fumiyuki Takahashi; Motoyasu Kato; Yoichiro Mitsuishi; Ken Tajima; Hiroaki Ihara; Moulid Hidayat; Aditya Wirawan; Yoshika Koinuma; Daisuke Hayakawa; Shigehiro Yagishita; Ryo Ko; Tadashi Sato; Norihiro Harada; Yuzo Kodama; Fariz Nurwidya; Shinichi Sasaki; Shin-Ichiro Niwa; Kazuhisa Takahashi
Journal:  Lung       Date:  2018-06-20       Impact factor: 2.584

7.  The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma.

Authors:  A L da Silva; R F Magalhães; V C Branco; J D Silva; F F Cruz; P S Marques; T P T Ferreira; M M Morales; M A Martins; P C Olsen; P R M Rocco
Journal:  Br J Pharmacol       Date:  2016-02-25       Impact factor: 8.739

8.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

9.  Multilayered polymer-coated carbon nanotubes to deliver dasatinib.

Authors:  Thomas L Moore; Stuart W Grimes; Robert L Lewis; Frank Alexis
Journal:  Mol Pharm       Date:  2013-12-09       Impact factor: 4.939

10.  Molecular dissection of AKT activation in lung cancer cell lines.

Authors:  Yanan Guo; Jinyan Du; David J Kwiatkowski
Journal:  Mol Cancer Res       Date:  2013-01-14       Impact factor: 5.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.